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Abstract
Background: The evidence for systemic treatments for severe childhood eczema is limited and largely based on
extrapolation of data from adult studies. Current therapies are often immunosuppressant and may be associated with
both short- and long-term side effects. There is increasing in vitro and murine-model evidence for the role of IgE in the
immunopathogenesis of atopic eczema. The aim of the study is to assess whether anti-IgE treatment (omalizumab)
improves eczema, compared to placebo.
Methods/design: The Atopic Dermatitis Anti-IgE Paediatric Trial (ADAPT) is a randomised, double-blind,
placebo-controlled study assessing the role of anti-IgE in the management of severe paediatric eczema. Children with
severe atopic eczema, with an objective SCORing Atopic Dermatitis (SCORAD) score of over 40 will be recruited. These
children are candidates for systemic therapy, have failed systemic therapy or have experienced side effects from systemic
therapy. Sixty-two patients aged between 4 and 19 years will receive anti-IgE for 6 months. The primary outcome
measure will be the validated eczema score, the objective SCORAD at 24 weeks. This study has 90% power to detect a
33% relative reduction in SCORAD between active and placebo groups, with 5% significance.
Discussion: IgE may have a role to play in eczema, particularly in childhood. This forms the basis for the hypothesis that
anti-IgE may be an effective treatment in this patient population.
This will be the largest study to evaluate the efficacy of anti-IgE (omalizumab) versus placebo in children with severe
eczema. The findings will help to clarify the role of anti-IgE as a potential treatment option in patients with severe
childhood eczema.
Trial registration: European Clinical Trials Database (EudraCT) Number: 2010-020841-29. Assigned on 14 May 2010.
ISRCTN Registry, Identifier: ISRCTN15090567. Retrospectively assigned on 3 December 2014.
ClinicalTrials.gov, Identifier: NCT02300701. First received 21 November 2014.
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Background
Atopic eczema (AE) (or atopic dermatitis) is an inflam-
matory, chronically relapsing, pruritic skin disease. The
prevalence in the United Kingdom (UK) is 16% for 6 to
7-year-olds (with 2.2% classed as severe) and 10.6% for
13 to 14-year-olds (with 1.5% classed as severe) [1]. AE
is associated with a significant economic and psycho-
social burden.
A complex interaction between genetics, environment
and immunology define the pathophysiology of AE.
There is increasing in vitro and murine-model evidence
for the role of IgE in the immunopathogenesis of atopic
dermatitis, with higher IgE levels linked with more se-
vere disease [2, 3]. IgE is likely to be of more relevance
in paediatric disease than in adult disease, where AE is
thought to become less allergen-driven and more ‘auto-
reactive’ [4]. This study focusses on a paediatric atopic
population, to target patients in whom IgE is more likely
to be relevant.
The management of AE includes the identification and
elimination of trigger factors, appropriate use of topical
treatments, and adequate patient education. When sys-
temic therapy is required, systemic immunosuppressants,
such as ciclosporin, azathioprine, and methotrexate, have
been used [5]. However there is limited published evi-
dence in childhood practice to guide clinical use. In
addition, most of these drugs are not licensed for use in
patients with severe AE in many countries. With the po-
tential for serious side effects, these drugs are often not
recommended for long-term use.
Omalizumab (Xolair®, Novartis) is the only commercially
available anti-IgE antibody. It binds to human IgE, limiting
mast cell degranulation and inhibiting the release of inflam-
matory mediators. It is licensed in the European Union for
use in chronic spontaneous urticaria from the age of 12
years, and severe persistent allergic asthma from the age of
6 years [6]. Safety data suggests that Xolair® (omalizumab)
is well tolerated in children [7].
Our hypothesis is that anti-IgE will reduce the levels
of IgE in children with severe AE and alleviate their
symptoms.
Objectives
Primary objectives
1. To determine whether the intervention is associated
with an improvement in eczema severity, compared
to placebo.
Secondary objectives
1. To evaluate whether the intervention is associated
with a change in eczema severity, eczema quality of
life and coexisting allergic disease
2. To assess whether it is safe and well tolerated in
eczema
3. To investigate whether the intervention is associated
with fewer eczema exacerbations and infective
episodes of eczema
4. To determine the change in reactivity to allergens
Methods/design
Study design
The Atopic Dermatitis Anti-IgE Paediatric Trial (ADAPT)
is a randomised, double-blind, placebo-controlled study. It
uses a hub and spoke method of recruitment where treat-
ment will be delivered at a single centre, but recruitment
will occur from hospitals in and around London, United
Kingdom. The trial will test the superiority of anti-IgE
(omalizumab) versus placebo in the treatment of severe
childhood eczema. The protocol was designed in accord-
ance with the SPIRIT (Standard Protocol Items: Recom-
mendations for Interventional Trials) guidelines for
interventional trials (Additional file 1: Figure S1; and
Additional file 2: Figure S2).
Sixty-two children, aged 4–19 years, with severe eczema
will be enrolled in the study which is based at Guy’s and St.
Thomas’ NHS Foundation Trust, London, United Kingdom.
Study population
The study population will be children with severe AE,
who are candidates for systemic therapy for AE. Children
will also be eligible if they have failed systemic therapy, or
have experienced side effects from systemic therapy.
Inclusion criteria
1. Aged 4–19 years
2. Severe eczema with (1) an objective SCORing
Atopic Dermatitis (SCORAD, a validated eczema
severity score) score of over 40, which is (2)
unresponsive to optimal topical therapy (potent
topical steroids and/or topical calcineurin inhibitors)
or systemic therapy, with (3) no impression of lack
of compliance, (4) a (Children’s) Dermatology Life
Quality Index Questionnaire ((C)DLQI) score of ≥10
and (5) where active skin infection has been ruled
out and/or adequately treated
3. A raised specific IgE (SpIgE) (>0.35 IU/ml or kUA/L)
or skin-prick test (SPT) (>3 mm) to at least one food
allergen or one aeroallergen and/or
4. The clinical impression that allergic exposures cause
worsening eczema
5. Total IgE level >300 IU/ml or kU/L
6. Clinically proven IgE-mediated allergic disease in-
cluding at least one of the following: (1) immediate
hypersensitivity to a food as proven by raised SpIgE
or SPT greater than the 95% positive predictive value
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or ≥8 mm, or a positive double-blind, placebo-
controlled food challenge, (2)
allergic rhinoconjunctivitis as defined by
sensitisation to a respiratory allergen and a
clinical history of rhinoconjunctivitis symptoms
when exposed to the relevant allergen, (3)
allergic asthma: a history of a cough, wheeze or
shortness of breath that (a) was responsive to ther-
apy with bronchodilators on two or more
occasions in the previous 24 months, (b) required
one visit to a physician in the previous 24 months
and (c) occurred during the night, during early
morning or upon exercising in the intervals
between exacerbations at any time in the previous
12 months and (d) where allergic exacerbations can
be clinically related to an allergen exposure with a
corresponding positive SPT or SpIgE to the allergen
7. Written informed consent to participate, and assent
if appropriate
Exclusion criteria
Children will not be able to participate if (1) they and/or
their families are unable to comply with the regime of two
to four weekly injections and clinic visits, (2) there is evi-
dence of underlying immune compromise, autoimmune
disease, immune complex-mediated conditions, (3) there
is malignancy or a history of malignancy, (4) there is a
known cardiovascular or ischaemic cerebrovascular ab-
normality, (5) there is other serious or uncontrolled sys-
temic disease, (6) the subject is pregnant or lactating, (7)
there is a known history of hypersensitivity or anaphylaxis
to anti-IgE injections or its constituents; (8) there is insuf-
ficient understanding of the trial assessments, (9) they
have participated in a clinical trial of an investigational
medicinal product (CTIMP) in the previous 60 days or (if
known) four half-lives of the medication under investiga-
tion, whichever is the greater. In this case, entry may be
delayed until the appropriate time or (10) the investigator
feels that there is a good clinical reason why the child
would be unsuitable for the study.
Recruitment
Sixty-two children with severe AE, will be enrolled into
the study which is based at Guy’s and St. Thomas’ NHS
Foundation Trust. A hub and spoke method of recruit-
ment will be employed. Referring hospitals from in and
around London will be able to refer patients to the study
team. Recruitment will be open to participants in the
UK who are willing to travel to the central treatment
centre for their treatment and follow-up visits.
Intervention
Each participant will be enrolled for 48 weeks, consisting
of a 24-week treatment period and a 24-week follow-up
period. A detailed timeline of the study is shown in the
Gantt chart in Additional file 3: Figure S3.
The active treatment is omalizumab (Xolair®) injection,
manufactured by Novartis and provided as 150-mg
single-use vial. The manufacturer also provided the
comparator. Placebo is formulated to be comparable in
appearance to the omalizumab and contains all of the
same excipients except the drug substance. The dose
and dosing frequency of omalizumab (Xolair®) or pla-
cebo will be determined by baseline total IgE (range: 30
to 1500 IU/ml), measured before treatment commences,
and body weight (kg) at the randomisation visit. The
dose of omalizumab (Xolair®) will be calculated using
the latest manufacturer’s dosing tables (according to the
current Summary of Product Characteristics) [8]. The
dose of Xolair® (omalizumab) stated on the table, closest
to that child’s weight and IgE levels, is used. Doses are
75, 150, 225, 300, 450, 525 or 600 mg every 2 or 4
weeks. The equivalent volume for placebo doses will
be calculated in the same way. Participants will re-
main on the same dose throughout the 24 weeks of
treatment. Treatment is administered subcutaneously
in the deltoid region or the thigh as one to four in-
jections depending on the dose. Anaesthesia using
topical local anaesthetic (lidocaine cream) or ethyl
chloride spray can be used prior to the injection,
according to patient preference.
Randomisation and blinding
Participants who consent to participate and who fulfil
the eligibility criteria are randomly allocated to receive
either omalizumab (Xolair®) or placebo in a 1:1 alloca-
tion ratio using a secure web-based randomisation
system. The allocation sequence is computer-generated
by the UK Clinical Research Collaboration (UKCRC)-
registered King’s College London Clinical Trials Unit in
conjunction with an independent statistician. Partici-
pants are allocated to treatment group using minimisa-
tion with variables IgE (≤1500, >1500 IU/ml) and age
(below 10 years or 10 years and older).
Blinding is maintained by strictly adhering to estab-
lished procedures to maintain separation between staff
who take outcome measurements and staff who deliver
the treatment. All study team physicians, researchers
and research nurses involved in primary outcome assess-
ments, as well as participants and their families, are
blinded to treatment allocation until the primary analysis
is completed. To ensure that these individuals remain
blinded to treatment allocation, randomisation details
are sent electronically to the independent pharmacy
team, and the preparation and administration of the
treatment will be restricted to a group of trained clinical
staff. Unblinded clinical staff are assigned to collect and
Chan et al. Trials  (2017) 18:136 Page 3 of 7
then return used vials of active or placebo to pharmacy.
Preparation and administration of treatment by unblinded
staff will occur in a closed treatment room, separate from
the main clinical area. Entry to this room is barred to
blinded staff during the preparation and administration of
the treatment by unblinded staff. Unblinded clinical staff
will not be involved in trial-related primary outcome
assessments to minimise the risk of disclosing the alloca-
tion of treatment. Staff members who obtain outcome
measurements are not involved in any of the steps involv-
ing handling of the intervention.
All patients will be provided with an emergency card
with relevant contact details to be carried for the
duration of the trial. Code break will be provided in clin-
ically relevant situations to clinicians, by the pharmacy
department.
The study statistician will analyse the data blinded to
treatment allocation.
Concomitant medications
Participants may continue to take their conventional
treatments for AE during the course of the study. Con-
comitant AE medications would include topical treat-
ments including any emollients, bath additives, topical
steroids, topical calcineurin inhibitors, wet wraps and
systemic treatment.
During treatment with omalizumab (Xolair®)/placebo,
the participants/parents will monitor the child’s AE at
home and, if there is any deterioration, this would trig-
ger the participants/parents to contact the study team to
discuss drug doses or a reassessment and modification
of therapy. An exacerbation will be identified and man-
aged, and any additional therapy or changes in doses of
existing treatment will be recorded.
Any medication required for any ongoing illness,
contraception and any rescue medications will also be
permitted and recorded. Female patients who have
attained menarche will undergo a pregnancy test at the
baseline and randomisation visits.
Outcomes
Details of the primary and secondary outcomes of the
study are summarised in Additional file 4: Table S1.
Primary outcome
Objective SCORAD
This will be based upon the assessment of the objective
SCORAD (SCORing Atopic Dermatitis) score after 24
weeks of treatment. Further assessments at 36 and 48
weeks (post-treatment reviews) will be performed.
The objective SCORing Atopic Dermatitis (eczema
severity score) is a validated clinical tool used to assess
the extent and severity of eczema [9]. It evaluates six
clinical characteristics to determine disease severity: (1)
erythema, (2) edema/papulation, (3) oozing/crust, (4)
excoriation, (5) lichenification and (6) dryness. The
maximum score is 83.
Secondary outcomes
Treatment failure
Treatment failure will be defined in patients who, after the
first 12 weeks of treatment, have persistent severe eczema
despite two courses of rescue therapy with oral prednisol-
one (0.5 to 1 mg/kg/day of oral prednisolone for a week at
a maximum dose of 40 mg/day, followed by a week at 50%
of this dose).
Alternative systemic therapy
An assessment will be made of patients in whom (1) alter-
native systemic therapy has been started as a result of treat-
ment failure as defined above or (2) where alternative
systemic therapy is started after 12 weeks, and by 30 weeks.
Eczema quality of life
This will be assessed by the Patient-oriented Eczema
Measure Questionnaire (POEM) and the (Children’s)
Dermatology Life Quality Index Questionnaire (C)DLQI.
The POEM is a validated, patient-derived assessment
measure for monitoring atopic eczema severity over the
past week [10]. The questionnaire has seven items, each
with a 5-point scale from no days to every day. The
scores range from 0 to 28. The data will be collected at
baseline, 4-weekly during treatment up to 24 weeks, and
at 36 and 48 weeks.
The (C)DLQI is a validated questionnaire designed to
measure the condition of the participant’s skin over the
past week [11]. The questionnaire has 10 questions and
the total score ranges from 0 to 30 [12]. The information
will be followed up at baseline, 4-weekly during treat-
ment up to 24 weeks, and at 36 and 48 weeks.
Eczema severity
This will be assessed by the objective and subjective
SCORAD scores, and the Eczema Area and Severity
Index (EASI).
The subjective SCORAD score is an add-on score to
the objective SCORAD score, which also assesses sub-
jective symptoms of pruritus and sleep loss [13], each on
a scale of 0 to 10 [13]. The subjective score adds up to
an additional 20 points to the objective SCORAD score.
The EASI is an investigator-assessed instrument to
measure the extent (area) and severity of atopic eczema
[14]. The severity of four features (erythema, edema/
papulation, excoriation and lichenification) are scored
from 0 to 3 (none, mild, moderate and severe, respect-
ively) with half-steps allowed, in a representative patch
of eczema in four regions (head/neck, upper limbs,
trunk, lower limbs). The percentage area affected is
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calculated. The EASI scores range from 0 to 72, and
higher scores represent more severe eczema.
Effect on coexisting allergic disease
This will be assessed by the Paediatric Allergic Disease
Quality of Life Questionnaire (PADQLQ), a measure of
health-related quality of life that encompasses effects of
allergic conditions on a child’s or teenager’s eyes, ears,
nose, lungs, skin, emotions, and everyday activities over
the past week [15]. The PADQLQ contains 26 questions,
with a 7-point scale from ‘not troubled’ to ‘extremely
troubled’.
Number of eczema exacerbations
The number of eczema exacerbations will be recorded.
Exacerbations will be defined as clinician-diagnosed ex-
acerbation of eczema or increase in the SCORAD score by
15 points from the last recorded SCORAD score with pa-
tient/parent/guardian perception of worsening eczema.
Infective episodes of eczema
Infective episodes of eczema will be defined as clinician-
diagnosed and treated infective episode of eczema, or
clinically apparent, culture-positive infective exacerbations.
Total and allergen-specific IgE (SpIgE)
This will be determined at screening and at 24 weeks.
Reactivity to food and aeroallergens
The SPT is an assessment of the allergic response to
specific food and aeroallergens. The SPT introduces a
tiny amount of allergen into the skin, eliciting a small,
localised allergic response in the form of a wheal and
flare at the site of testing [16, 17].
Steroid cream usage
The amount of potent steroid creams and calcineurin in-
hibitors used will be assessed. Tubes of creams are
weighed at each visit using digital scales. The frequency of
use per day and per week since the last visit, and the body
surface area covered, will be recorded.
Data collection and management
Data will be collected on source data worksheets and
stored in the patient’s medical notes, and will be tran-
scribed to the electronic Case Report Form (eCRF)
system. The eCRF will be designed and maintained by
the King’s Clinical Trials Unit using the InferMed
MACRO system (Version 4.0), which is compliant with
Good Clinical Practice (GCP) and 21 CRF Part 11. At
the end of the study, the eCRF system will be locked and
data exported for final analysis. Patient data will be
anonymised. All anonymised data will be stored on a
password-protected computer. All trial data will be
stored and archived in line with the Medicines for
Human Use (Clinical Trials) Amended Regulations 2006
as defined in the King’s Health Partners Clinical Trials
Office Archiving Standard Operating Procedure.
Statistics
Sample size
Omalizumab is administered at 2- to 4-weekly intervals,
by subcutaneous injection, at a suitable health care facil-
ity. It is available in the UK under a negotiated patient
access scheme for asthma and chronic urticaria. A rea-
sonable treatment benefit would be required for omali-
zumab to be adopted into practice. We aim to detect a
33% relative reduction in SCORAD scores. In order to
detect a change in the SCORAD score of 13.5 points be-
tween the treatment arms, assuming an SD of 15 [18]
with 5% significance and 90% power, and incorporating
a 15% dropout rate, we aim to recruit 62 participants
(31 to each arm).
Analysis
A Consolidated Standards of Reporting Trials (CONSORT)
flow chart will be constructed and will include the number
of eligible patients, number of patients agreeing to
enter the trial, number of participants withdrawing and
the number included in the analyses [19].
Baseline characteristics will be summarised and tabu-
lated by treatment arm. The analysis will follow an
intention-to-treat (ITT) principle and participants will
be analysed in the arm to which they were allocated re-
gardless of subsequent treatment received. The number
lost to follow-up will be tabulated by treatment arm and
visit. The proportions of participants missing objective
SCORAD values will be summarised in each arm and at
each time point. The baseline characteristics (age, gen-
der, objective and subjective SCORAD, Body Mass Index
(BMI), asthma (Y/N), food allergy (Y/N), rhinoconjunc-
tivitis (Y/N) and referral source (self-referred/tertiary) of
those missing follow-up will be compared to those with
complete follow-up. The recorded reasons for with-
drawal from the trial will be summarised [20].
A linear mixed model will be used to obtain an esti-
mate for the mean difference in objective SCORAD
scores between the two treatment groups. Participant
will be included as a random intercept (investigating
adding a random slope on time), time (investigating the
possibility of linearising this effect across 8, 12, 16, 20
and 24 weeks), time-by-group interaction, baseline ob-
jective SCORAD score, IgE (≤1500, >1500 IU/ml) and
age (below 10 years or 10 years and older) as fixed effect.
An overall treatment effect for the objective SCORAD
score at 24 weeks will be estimated. A number of sensi-
tivity analyses will be performed to estimate the treat-
ment effect adjusting for use of topical steroids and
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alternative systemic therapy. A complier average causal
effect (CACE) will be performed where ‘complier’ will be
defined as a participant who completes more than 50%
of injections [21].
Secondary analysis will be based on the ITT population
and primarily focussed on the outcome at week 24. Subject-
ive SCORAD scores will be analysed in a similar manner as
for objective SCORAD scores. For all other outcomes we
will only adjust for the minimisation variables IgE (≤1500,
>1500 IU/ml), age (below 10 years or 10 years and older)
and baseline data (as appropriate). Binary outcomes will
be analysed using a logistic regression model and count
outcomes using Poisson regression, negative binomial re-
gression or zero-inflated Poisson, as appropriate, and con-
tinuous outcomes using a linear regression model.
Adverse events will be tabulated separately by type (adverse
events, adverse reaction, unexpected adverse reaction, serious
adverse event, serious adverse reaction or unexpected serious
adverse reactions). These will be summarised overall (0–48
weeks) and the time of occurrence will be explored by rando-
mised interventionwhere appropriate.
A detailed statistical analysis plan has been devel-
oped in conjunction with the protocol and is available
[Reference from Trials if accepted].
Discussion
The management of AE necessitating systemic therapy is
currently an area of intense interest. When systemic
therapy is required in childhood AE, systemic immuno-
suppressants have been used with limited evidence, and
in many cases as an unlicensed indication [5].
There is increasing evidence for the role of IgE in the
immunopathogenesis in AE. Omalizumab (Xolair®, Novar-
tis) is the only commercially available anti-IgE antibody.
ADAPT is the largest randomised, double-blind, placebo-
controlled study to date evaluating anti-IgE (omalizumab)
in severe childhood AE. The aim is to definitively assess the
role of anti-IgE as an alternative systemic treatment for AE.
Trial status
The ADAPT study received favourable ethical opinion
on 7 July 2011 and local R&D approvals were obtained
on 11 November 2014. Participant recruitment started
on 20 November 2014 and is ongoing.
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